Adiponectin inhibits osteoclastogenesis by suppressing NF-κB and p38 signaling pathways

Biochem Biophys Res Commun. 2018 Sep 10;503(3):2075-2082. doi: 10.1016/j.bbrc.2018.07.162. Epub 2018 Aug 11.

Abstract

Adiponectin (APN) has been shown to play a key role in regulating bone mineral density (BMD). Nevertheless, the effects of APN on receptor activator of NF-κB ligand (RANKL)-induced osteoclast formation and mechanism of regulation are not entirely clear. The study, therefore, aimed to evaluate the effect of APN on osteoclastogenesis. Our results showed that APN inhibits osteoclastogenesis and resorption function in vitro by suppressing nuclear factor-κB (NF-κB) and p38 signaling pathways, which is essential for osteoclast formation. Moreover, APN blocked the formation of F-actin rings and attenuated osteoclast-mediated bone resorptive function. Therefore, we concluded that APN may provide a potential treatment for osteoclast-related diseases, such as osteoporosis.

Keywords: Adiponectin; Nuclear factor-κB signaling; Osteoclastogenesis; Receptor activator of nuclear factor-κB ligand; p38 signaling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiponectin / administration & dosage
  • Adiponectin / pharmacology*
  • Animals
  • Cell Survival / drug effects
  • Dose-Response Relationship, Drug
  • Mice
  • NF-kappa B / antagonists & inhibitors*
  • NF-kappa B / metabolism
  • Osteoclasts / drug effects
  • Osteogenesis / drug effects*
  • RAW 264.7 Cells
  • Receptor Activator of Nuclear Factor-kappa B / antagonists & inhibitors
  • Receptor Activator of Nuclear Factor-kappa B / metabolism
  • Signal Transduction / drug effects
  • Structure-Activity Relationship
  • p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors*
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Adiponectin
  • NF-kappa B
  • Receptor Activator of Nuclear Factor-kappa B
  • p38 Mitogen-Activated Protein Kinases